Logo image of CRDF

CARDIFF ONCOLOGY INC (CRDF) Stock Fundamental Analysis

NASDAQ:CRDF - Nasdaq - US14147L1089 - Common Stock - Currency: USD

2.82  +0.11 (+4.06%)

After market: 2.87 +0.05 (+1.77%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRDF. CRDF was compared to 567 industry peers in the Biotechnology industry. While CRDF has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRDF is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRDF has reported negative net income.
In the past year CRDF has reported a negative cash flow from operations.
CRDF had negative earnings in each of the past 5 years.
In the past 5 years CRDF always reported negative operating cash flow.
CRDF Yearly Net Income VS EBIT VS OCF VS FCFCRDF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of CRDF (-46.77%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -54.80%, CRDF is in the better half of the industry, outperforming 62.61% of the companies in the same industry.
Industry RankSector Rank
ROA -46.77%
ROE -54.8%
ROIC N/A
ROA(3y)-43.63%
ROA(5y)-33.32%
ROE(3y)-50.23%
ROE(5y)-37.7%
ROIC(3y)N/A
ROIC(5y)N/A
CRDF Yearly ROA, ROE, ROICCRDF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRDF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDF Yearly Profit, Operating, Gross MarginsCRDF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

CRDF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRDF has more shares outstanding
Compared to 5 years ago, CRDF has more shares outstanding
CRDF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRDF Yearly Shares OutstandingCRDF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRDF Yearly Total Debt VS Total AssetsCRDF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of 1.73, we must say that CRDF is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.73, CRDF is doing good in the industry, outperforming 70.90% of the companies in the same industry.
There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.73
ROIC/WACCN/A
WACC10.04%
CRDF Yearly LT Debt VS Equity VS FCFCRDF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CRDF has a Current Ratio of 7.08. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CRDF (7.08) is better than 69.31% of its industry peers.
A Quick Ratio of 7.08 indicates that CRDF has no problem at all paying its short term obligations.
CRDF's Quick ratio of 7.08 is fine compared to the rest of the industry. CRDF outperforms 69.84% of its industry peers.
Industry RankSector Rank
Current Ratio 7.08
Quick Ratio 7.08
CRDF Yearly Current Assets VS Current LiabilitesCRDF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

CRDF shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.15%.
CRDF shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.74%.
Measured over the past years, CRDF shows a very strong growth in Revenue. The Revenue has been growing by 23.27% on average per year.
EPS 1Y (TTM)-2.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.76%
Revenue 1Y (TTM)40.74%
Revenue growth 3Y23.8%
Revenue growth 5Y23.27%
Sales Q2Q%-3.21%

3.2 Future

CRDF is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.57% yearly.
The Revenue is expected to grow by 173.05% on average over the next years. This is a very strong growth
EPS Next Y15.21%
EPS Next 2Y-0.79%
EPS Next 3Y-12.19%
EPS Next 5Y-16.57%
Revenue Next Year-43.81%
Revenue Next 2Y-47.74%
Revenue Next 3Y-41.85%
Revenue Next 5Y173.05%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRDF Yearly Revenue VS EstimatesCRDF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CRDF Yearly EPS VS EstimatesCRDF Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRDF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDF Price Earnings VS Forward Price EarningsCRDF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDF Per share dataCRDF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

CRDF's earnings are expected to decrease with -12.19% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.79%
EPS Next 3Y-12.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRDF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIFF ONCOLOGY INC

NASDAQ:CRDF (5/2/2025, 8:00:01 PM)

After market: 2.87 +0.05 (+1.77%)

2.82

+0.11 (+4.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners36.86%
Inst Owner Change4.45%
Ins Owners1.99%
Ins Owner Change29.2%
Market Cap187.61M
Analysts83.08
Price Target14.48 (413.48%)
Short Float %28.3%
Short Ratio13.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.99%
Min EPS beat(2)9.22%
Max EPS beat(2)10.75%
EPS beat(4)3
Avg EPS beat(4)7.46%
Min EPS beat(4)-2.99%
Max EPS beat(4)12.85%
EPS beat(8)6
Avg EPS beat(8)9.62%
EPS beat(12)9
Avg EPS beat(12)9.99%
EPS beat(16)11
Avg EPS beat(16)5.38%
Revenue beat(2)2
Avg Revenue beat(2)79.71%
Min Revenue beat(2)57.2%
Max Revenue beat(2)102.21%
Revenue beat(4)4
Avg Revenue beat(4)149.21%
Min Revenue beat(4)57.2%
Max Revenue beat(4)265.42%
Revenue beat(8)8
Avg Revenue beat(8)154.91%
Revenue beat(12)12
Avg Revenue beat(12)118.69%
Revenue beat(16)14
Avg Revenue beat(16)106.77%
PT rev (1m)-0.35%
PT rev (3m)29.09%
EPS NQ rev (1m)3.97%
EPS NQ rev (3m)17.28%
EPS NY rev (1m)0.83%
EPS NY rev (3m)14.57%
Revenue NQ rev (1m)10.21%
Revenue NQ rev (3m)26.88%
Revenue NY rev (1m)2.86%
Revenue NY rev (3m)6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 274.29
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.01
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.77%
ROE -54.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.63%
ROA(5y)-33.32%
ROE(3y)-50.23%
ROE(5y)-37.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.8%
Cap/Sales 11.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.08
Quick Ratio 7.08
Altman-Z 1.73
F-Score5
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)195.62%
Cap/Depr(5y)135.64%
Cap/Sales(3y)129.98%
Cap/Sales(5y)101.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.76%
EPS Next Y15.21%
EPS Next 2Y-0.79%
EPS Next 3Y-12.19%
EPS Next 5Y-16.57%
Revenue 1Y (TTM)40.74%
Revenue growth 3Y23.8%
Revenue growth 5Y23.27%
Sales Q2Q%-3.21%
Revenue Next Year-43.81%
Revenue Next 2Y-47.74%
Revenue Next 3Y-41.85%
Revenue Next 5Y173.05%
EBIT growth 1Y-7.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.04%
OCF growth 3YN/A
OCF growth 5YN/A